The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus.

@article{Yau2013TheFO,
  title={The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus.},
  author={Hanford Yau and Kathya Rivera and Romina Lomonaco and Kenneth Cusi},
  journal={Current diabetes reports},
  year={2013},
  volume={13 3},
  pages={
          329-41
        }
}
Since their approval, thiazolidinediones (TZDs) have been used extensively as insulin-sensitizers for the management of type 2 diabetes mellitus (T2DM). Activation of peroxisomal proliferator-activated receptor gamma (PPARγ) nuclear receptors by TZDs leads to a vast spectrum of metabolic and antiinflammatory effects. In the past decade, clinicians and scientists across the fields of metabolism, diabetes, liver disease (NAFLD), atherosclerosis, inflammation, infertility, and even cancer have had… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 31 CITATIONS

Current clinical evidence on pioglitazone pharmacogenomics

  • Front. Pharmacol.
  • 2013
VIEW 9 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Obesity and nonalcoholic fatty liver disease: current perspectives

  • Diabetes, metabolic syndrome and obesity : targets and therapy
  • 2018
VIEW 1 EXCERPT

References

Publications referenced by this paper.
SHOWING 1-10 OF 106 REFERENCES

Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus.

  • The Journal of clinical endocrinology and metabolism
  • 2010
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

Risk of Fracture with Thiazolidinediones: Disease or Drugs?

Marloes T. Bazelier, Peter Vestergaard, +4 authors Frank de Vries
  • Calcified Tissue International
  • 2012
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Thiazolidinediones and fractures: evidence from translating research into action for diabetes.

  • The Journal of clinical endocrinology and metabolism
  • 2010
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…